WALTHAM, Mass. — April 21, 2017 — Entasis Therapeutics, a leader in the discovery and development of breakthrough anti-infective products, today announced two oral presentations at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), which is being held April 22 – 25 in Vienna, Austria. Both presentations will highlight the preclinical profile of ETX2514, Entasis’ next-generation beta-lactamase inhibitor with an expanded spectrum of activity against Class A, C, and D beta-lactamases, as well as that of ETX2514SUL, the combination of ETX2514 with sulbactam which is being developed for the treatment of A. baumannii infections. ETX2514SUL is currently in Phase 1 clinical trials.
Details of the presentations are as follows:
Title: ETX2514: Responding to the global threat of nosocomial multidrug and extremely drug resistant Gram-negative pathogens
Date and Time: Monday April 24, 9:00 AM
Location: Hall K
Abstract #: 4097
Presenter: Dr. Ruben Tommasi
Title: Restoration of sulbactam activity against multidrug resistant Acinetobacter baumannii by the novel, broad spectrum β-lactamase inhibitor ETX2514 correlates with β-lactamase inhibition in vitro and in vivo
Date and Time: Monday April 24, 9:36 AM
Location: Hall K
Abstract #: 5942
Presenter: Dr. Alita Miller
ETX2514 is a potent and broad spectrum inhibitor of class A, C, and D beta-lactamases. ETX2514 restores the in vitro activity of multiple beta-lactams against Gram-negative, multi-drug resistant (MDR) pathogens. Entasis Therapeutics is developing ETX2514SUL, the combination of ETX2514 and sulbactam, for the treatment of severe A. baumannii infections. A. baumannii is a Gram-negative bacterium that causes severe infections which are associated with high mortality rates. A. baumannii infections are frequently multi-drug resistant and there is an urgent need to identify new safe and effective agents to treat affected patients. Sulbactam is a generic beta-lactam which has intrinsic activity against A. baumannii but suffers from widespread beta-lactamase-mediated resistance. In preclinical studies, ETX2514 restores sulbactam’s antimicrobial activity against A. baumannii. ETX2514SUL is currently in Phase 1 clinical trials.
About Entasis Therapeutics Inc.
Entasis Therapeutics is developing a portfolio of innovative cures for serious drug-resistant bacterial infections, a global health crisis affecting the lives of millions of patients. Entasis’ anti-infective discovery platform has produced a pipeline of meaningfully differentiated programs which target serious bacterial infections, including ETX2514SUL (targeting infections caused by Acinetobacter baumannii infections) and zoliflodacin (targeting the treatment of Neisseria gonorrhoeae infections) currently in the clinic. www.entasistx.com
MacDougall Biomedical Communications (781) 235-3060